BMY's Growth Trio Surges 42%, But Bridge-Year Risks Remain

What happened

Bristol-Myers Squibb's Q1 performance is tracking toward the upper end of 2026 guidance, driven by a 42% surge in its growth trio of Breyanzi, Camzyos, and Reblozyl to $1.28 billion. This strong execution reinforces the portfolio transition narrative, yet the DeepValue Master Report cautions that the near-term setup is a policy-fragile 'bridge year' requiring observable proof that Eliquis growth translates into stable gross margins. The report's WAIT rating reflects concern that Eliquis faces IRA price resets and a Medicaid free-supply agreement effective Jan 1, 2026, while Revlimid erosion accelerates after volume caps end on Jan 31, 2026. Consolidated non-GAAP gross margin guidance of 69-70% for 2026 is a key test: if growth is achieved via higher concessions, margins could break below the guided range and trigger a derating. Until Q1-Q2 2026 results confirm margin stability alongside revenue growth, the risk/reward remains skewed toward waiting for evidence that the bridge is structurally sound.

Implication

Investors should remain cautious. The article confirms growth portfolio momentum, but the DeepValue analysis identifies date-certain policy events (Eliquis Medicare price reset, Revlimid volume cap removal) that could compress margins. The thesis depends on gross margin staying 69-70% while Eliquis grows 10-15%. Until Q1 2026 results verify this, the stock's upside is capped by bridge-year uncertainty. A miss on margin could send the stock toward the $52 bear case. Patience is warranted.

Thesis delta

The news reinforces the growth portfolio's strong trajectory, but it does not alter the core bridge-year thesis. The key variable remains whether Eliquis volume defense translates into stable gross margins, not just revenue growth. The WAIT stance is unchanged; the next two quarters will be decisive.